A phase I dose-defining study for MK-2206 combined with gefitinib in NSCLC population enriched with EGFR mutation.
Chia-Chi Lin
No relevant relationships to disclose
Chong-Jen Yu
No relevant relationships to disclose
Chao-Chi Ho
No relevant relationships to disclose
Kuan-Yu Chen
No relevant relationships to disclose
Jin-Yuan Shih
No relevant relationships to disclose
Zhong-Zhe Lin
No relevant relationships to disclose
Yu-lin Lin
No relevant relationships to disclose
Wei-Yu Liao
No relevant relationships to disclose
Shoung-Hui Tsai
No relevant relationships to disclose
Li Yan
Stock Ownership - Merck Sharp & Dohme
James Chih-Hsin Yang
Research Funding - AstraZeneca; Merck Sharp & Dohme